Aspirin desensitization in patients with coronary artery disease: Cost savings

Med Intensiva. 2017 Oct;41(7):446-447. doi: 10.1016/j.medin.2016.09.012. Epub 2017 Feb 11.

[Article in English, Spanish]

Authors

J L Cubero¹, B Simó Sánchez², P Millán³, C Colás⁴

Affiliations

¹ Servicio de Alergia, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, España. Electronic address: jlcubero@salud.aragon.es.
² Servicio de Cardiología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
³ Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
⁴ Servicio de Alergia, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, España.

PMID: 28196671
DOI: 10.1016/j.medin.2016.09.012

No abstract available

Publication types

Letter

MeSH terms

Aspirin / administration & dosage
Aspirin / economics
Aspirin / therapeutic use*
Clopidogrel
Coronary Disease / drug therapy*
Coronary Disease / economics
Cost Savings
Desensitization, Immunologic* / economics
Drug Hypersensitivity / therapy*
Drug Substitution
Humans
Platelet Aggregation Inhibitors / administration & dosage
Platelet Aggregation Inhibitors / economics*
Platelet Aggregation Inhibitors / therapeutic use
Prasugrel Hydrochloride / economics
Purinergic P2Y Receptor Antagonists / economics
Salicylates / economics
Ticlopidine / analogs & derivatives
Ticlopidine / economics

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Salicylates
triflusal
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine
Aspirin